Fresenius Medical Care AG & Co. KGaA (FMS) Projected to Post Quarterly Earnings on Tuesday

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS - Get Free Report) is expected to be issuing its Q2 2025 quarterly earnings data before the market opens on Tuesday, July 29th. Analysts expect the company to announce earnings of $0.47 per share for the quarter.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported $0.44 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.43 by $0.01. Fresenius Medical Care AG & Co. KGaA had a net margin of 3.18% and a return on equity of 6.25%. The business had revenue of $5.54 billion during the quarter, compared to analyst estimates of $4.71 billion. On average, analysts expect Fresenius Medical Care AG & Co. KGaA to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Fresenius Medical Care AG & Co. KGaA Trading Down 1.3%

Fresenius Medical Care AG & Co. KGaA stock traded down $0.36 during mid-day trading on Friday, hitting $26.41. 319,698 shares of the stock were exchanged, compared to its average volume of 204,120. The company has a quick ratio of 1.08, a current ratio of 1.46 and a debt-to-equity ratio of 0.40. Fresenius Medical Care AG & Co. KGaA has a 12 month low of $17.93 and a 12 month high of $30.46. The firm's fifty day simple moving average is $28.00 and its two-hundred day simple moving average is $25.63.

Fresenius Medical Care AG & Co. KGaA Increases Dividend

The company also recently declared an annual dividend, which was paid on Friday, June 6th. Shareholders of record on Friday, May 23rd were issued a dividend of $0.7871 per share. This is a positive change from Fresenius Medical Care AG & Co. KGaA's previous annual dividend of $0.44. The ex-dividend date of this dividend was Friday, May 23rd. This represents a yield of 1.9%. Fresenius Medical Care AG & Co. KGaA's dividend payout ratio (DPR) is presently 50.89%.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the stock. Truist Financial raised their price target on shares of Fresenius Medical Care AG & Co. KGaA from $25.00 to $30.00 and gave the stock a "hold" rating in a report on Monday, May 12th. Wall Street Zen upgraded Fresenius Medical Care AG & Co. KGaA from a "hold" rating to a "strong-buy" rating in a report on Saturday, July 5th. Finally, Morgan Stanley reiterated an "underweight" rating on shares of Fresenius Medical Care AG & Co. KGaA in a report on Thursday, May 15th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, one has issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Fresenius Medical Care AG & Co. KGaA has an average rating of "Hold" and a consensus price target of $27.80.

Institutional Trading of Fresenius Medical Care AG & Co. KGaA

An institutional investor recently raised its position in Fresenius Medical Care AG & Co. KGaA stock. AQR Capital Management LLC increased its stake in Fresenius Medical Care AG & Co. KGaA (NYSE:FMS - Free Report) by 14.2% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 14,297 shares of the company's stock after acquiring an additional 1,777 shares during the quarter. AQR Capital Management LLC's holdings in Fresenius Medical Care AG & Co. KGaA were worth $356,000 at the end of the most recent reporting period. Institutional investors own 8.37% of the company's stock.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.